Selected articles
Articles for label Rušínová Lenka are displayed.. Show all articles
Complete and long‑term response of HER2 positive locally highly advanced metastatic breast cancer – case report
04/2019 MUDr. Lenka Rušinová; doc. MUDr. Renata Soumarová, Ph.D.; MUDr. Marián Liberko
Unfortunately, we are currently encountering locally very advanced and generalized breast cancers. However, due to systemic therapy and especially targeted therapy, we can see excellent long-term responses in patients with HER2 positive tumors. The discovery of novel products targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and the combination of this monoclonal antibody with the microtubule inhibitor T-DM1 (trastuzumab emtansine) has resulted in a statistically significant increase in overall survival and has changed metastatic HER2 positive breast cancer to chronic disease.
ENTIRE ARTICLE
Unfortunately, we are currently encountering locally very advanced and generalized breast cancers. However, due to systemic therapy and especially targeted therapy, we can see excellent long-term responses in patients with HER2 positive tumors. The discovery of novel products targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and the combination of this monoclonal antibody with the microtubule inhibitor T-DM1 (trastuzumab emtansine) has resulted in a statistically significant increase in overall survival and has changed metastatic HER2 positive breast cancer to chronic disease.
When and why to indicate breast cancer radiotherapy after neoadjuvant systemic therapy
04/2019 Doc. MUDr. Renata Soumarová, Ph.D.; MUDr. Lenka Rušínová
Adjuvant radiotherapy after both radical and partial mastectomy has an effect on local disease control as well as overall survival, as evidenced by large studies with long-term follow-up. However, postoperative radiotherapy indications for patients after neoadjuvant chemotherapy are controversial. This is due to a different tumor response to neoadjuvant treatment and a lack of prospective studies. Currently, when considering post-operative radiotherapy after neoadjuvant treatment, both the very accurate pre-treatment classification and the tumor characteristics including molecular subtypes and the definitive pathological classification must be taken into account. The most difficult decision is especially in the group of patients who have achieved a pathological complete response.
ENTIRE ARTICLE
Adjuvant radiotherapy after both radical and partial mastectomy has an effect on local disease control as well as overall survival, as evidenced by large studies with long-term follow-up. However, postoperative radiotherapy indications for patients after neoadjuvant chemotherapy are controversial. This is due to a different tumor response to neoadjuvant treatment and a lack of prospective studies. Currently, when considering post-operative radiotherapy after neoadjuvant treatment, both the very accurate pre-treatment classification and the tumor characteristics including molecular subtypes and the definitive pathological classification must be taken into account. The most difficult decision is especially in the group of patients who have achieved a pathological complete response.